Search

Your search keyword '"Choi, Donghoon"' showing total 1,482 results
Start Over Author "Choi, Donghoon" Language english
1,482 results on '"Choi, Donghoon"'

2. Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial

Author

Hong, Sung-Jin, Lee, Yong-Joon, Kang, Woong Chol, Hong, Bum-Kee, Lee, Jong-Young, Lee, Jin-Bae, Yang, Tae-Hyun, Yoon, Junghan, Lee, Seung-Jun, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, and Hong, Myeong-Ki

Published
2024
Full Text
View/download PDF

5. Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea

Author

Hong, Sung-Jin, Lee, Seung-Jun, Lee, Sang-Hyup, Lee, Jong-Young, Cho, Deok-Kyu, Kim, Jin Won, Kim, Sang Min, Hur, Seung-Ho, Heo, Jung Ho, Jang, Ji-Yong, Koh, Jin Sin, Won, Hoyoun, Lee, Jun-Won, Hong, Soon Jun, Kim, Dong-Kie, Choe, Jeong Cheon, Lee, Jin Bae, Kim, Soo-Joong, Yang, Tae-Hyun, Lee, Jung-Hee, Hong, Young Joon, Ahn, Jong-Hwa, Lee, Yong-Joon, Ahn, Chul-Min, Kim, Jung-Sun, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo, and Kim, Byeong-Keuk

Published
2024
Full Text
View/download PDF

11. Correction: Comparison of 2‑year mortality according to obesity in stabilized patients with type 2 diabetes mellitus after acute myocardial infarction: results from the DIAMOND prospective cohort registry

Author

Won, Ki‑Bum, Hur, Seung‑Ho, Cho, Yun‑Kyeong, Yoon, Hyuck‑Jun, Nam, Chang‑Wook, Kim, Kwon‑Bae, Bae, Jang‑Ho, Choi, Dong‑Ju, Ahn, Young‑Keun, Park, Jong‑Seon, Kim, Hyo‑Soo, Choi, Rak‑Kyeong, Choi, Donghoon, Kim, Joon‑Hong, Han, Kyoo‑Rok, Park, Hun‑Sik, Choi, So‑Yeon, Yoon, Jung‑Han, Kwon, Hyeon‑Cheol, Rha, Seung-Woon, Hwang, Kyung‑Kuk, Lim, Do‑Sun, Jung, Kyung‑Tae, Oh, Seok‑Kyu, Lee, Jae‑Hwan, Shin, Eun‑Seok, and Kim, Kee‑Sik

Published
2023
Full Text
View/download PDF

13. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial

Author

Hong, Sung-Jin, Lee, Seung-Jun, Suh, Yongsung, Yun, Kyeong Ho, Kang, Tae Soo, Shin, Sanghoon, Kwon, Sung Woo, Lee, Jun-Won, Cho, Deok-Kyu, Park, Jong-Kwan, Bae, Jang-Whan, Kang, Woong Cheol, Kim, Seunghwan, Lee, Yong-Joon, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, and Hong, Myeong-Ki

Published
2024
Full Text
View/download PDF

16. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Author

Lee, Bom, Hong, Sung-Jin, Rha, Seung-Woon, Heo, Jung Ho, Hur, Seung-Ho, Choi, Hyun Hee, Kim, Kyung-Jin, Kim, Ju Han, Kim, Hyun Kuk, Kim, Ung, Choi, Yu Jeong, Lee, Yong-Joon, Lee, Seung-Jun, Ahn, Chul-Min, Ko, Young-Guk, Kim, Byeong-Keuk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo, and Kim, Jung-Sun

Published
2023
Full Text
View/download PDF

17. Association of Prophylactic Distal Perfusion Cannulation With Mortality in Patients Receiving Venoarterial Extracorporeal Membrane Oxygenation

Author

Lee, Hyeok-Hee, Jang, Woo Jin, Ahn, Chul-Min, Chun, Woo Jung, Oh, Ju Hyeon, Park, Yong Hwan, Lee, Seung-Jun, Hong, Sung-Jin, Yang, Jeong Hoon, Kim, Jung-Sun, Kim, Hyeon Chang, Kim, Byeong-Keuk, Yu, Cheol Woong, Kim, Hyun-Joong, Bae, Jang-Whan, Ko, Young-Guk, Choi, Donghoon, Gwon, Hyeon-Cheol, Hong, Myeong-Ki, and Jang, Yangsoo

Published
2023
Full Text
View/download PDF

20. Treat-to-target versus high-intensity statin treatment in patients with or without diabetes mellitus: a pre-specified analysis from the LODESTAR trial

Author

Hong, Myeong-Ki, Choi, Donghoon, Ko, Young-Guk, Kim, Byeong-Keuk, Kim, Jung-Sun, Ahn, Chul-Min, Hong, Sung-Jin, Lee, Seung-Jun, Lee, Yong-Joon, Hong, Bum-Kee, Kwon, Hyuck Moon, Kim, Jong-Youn, Min, Pil Ki, Yoon, Young Won, Lee, Byoung Kwon, Rim, Se-Joong, Choi, Eui-Young, CholKang, Woong, Oh, Pyung Chun, Lee, Jong-Young, Lee, Jin-Bae, Kim, Kee Sik, Choi, Ji Yong, Ryu, Jae Kean, Hong, Seung Pyo, Kim, Chang Yeon, Yang, Tae-Hyun, Cho, Hyung-Jin, Yoon, Junghan, Ahn, Min-Soo, Ahn, Sung Gyun, Lee, Jun-Won, Son, Jung-Woo, Jang, Yangsoo, Yoon, Hyuck-Jun, Lee, Cheol Hyun, Hwang, Jongmin, Cho, Yun-Kyeong, Hur, Seung-Ho, Han, Seongwook, Nam, Chang-Wook, Kim, Hyoungseop, Park, Hyoung-Seob, Kim, In-Cheol, Cho, Yun-Hyeong, Jeong, Hyeon-Ju, Kim, Jin-Ho, Lim, Chewan, Suh, Yongsung, Hwang, Eui Seok, Lee, Ji Hyun, Lee, Sung Yun, Kwon, Sung Uk, Kim, Song-Yi, Park, Keun-Ho, Ki, Hyun Kuk, and Kang, Woong Chol

Published
2023
Full Text
View/download PDF

21. Perioperative Antiplatelet Strategy in Patients Undergoing Noncardiac Surgery Within One Year After Percutaneous Coronary Intervention

Author

Lee, Sang-Hyup, Kim, Choongki, Shin, Sanghoon, Kim, Hyeongsoo, Park, Jong-Kwan, Oh, Seung-Jin, Ahn, Sung Gyun, Cho, Sungsoo, Lee, Oh-Hyun, Moon, Jae Youn, Won, Hoyoun, Suh, Yongsung, Cho, Yun-Hyeong, Cho, Jung Rae, Lee, Byoung-Kwon, Lee, Yong-Joon, Lee, Seung-Jun, Hong, Sung-Jin, Shin, Dong-Ho, Ahn, Chul-Min, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo, and Kim, Jung-Sun

Published
2023
Full Text
View/download PDF

25. Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial

Author

Park, Jong-Il, Lee, Seung-Jun, Lee, Yong-Joon, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Kim, Jung-Sun, Hong, Bum-Kee, Lee, Jung-Hee, Kim, Ung, Cho, Yun-Hyeong, Shin, Won-Yong, Lim Jang, Sang-Wook Yangsoo, Kang, Woong-Chol, Park Jung, Yongwhi Young Hoon, Lee, Sung-Yoon, Kim, Kyoung Jin, Hong, Soon-Jun, Yun, Kyeong Ho, Heo, Jung Ho, Rha, Seung-Woon, Choi, Woong Gil, Lee, Wang Soo Lee, Jung, Jinok, Choi, Sunghoon, Cho, Youn Haeng, Park, Woo Jung, Youn, Changhwan, Hur, Seung Ho, Choi, Hyun Hee, Kim, Ju Han, Kim, Hyun Kuk, Choi, Yu-Jung, Lim, Sang-Wook, Park, Yongwhi, and Jang, Yangsoo

Published
2023
Full Text
View/download PDF

29. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Author

Kim, Byeong-Keuk, Hong, Sung-Jin, Lee, Yong-Joon, Hong, Soon Jun, Yun, Kyeong Ho, Hong, Bum-Kee, Heo, Jung Ho, Rha, Seung-Woon, Cho, Yun-Hyeong, Lee, Seung-Jun, Ahn, Chul-Min, Kim, Jung-Sun, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, and Hong, Myeong-Ki

Published
2022
Full Text
View/download PDF

32. Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial

Author

Kook, Hyungdon, Yu, Cheol Woong, Choi, Donghoon, Ahn, Tae Hoon, Chang, Kiyuk, Cho, Jin-Man, Kim, Soo-Joong, Park, Chang Gyu, Cho, Deok-Kyu, Kim, Sang-Hyun, Lee, Han Cheol, Jin, Han-Young, Chae, In-Ho, Kwon, Kihwan, Ahn, Sung Gyun, Kim, Ju Han, Lee, Sang-Rok, Kim, Jeong-Su, Kim, Seok Yeon, and Lim, Sang Wook

Published
2022
Full Text
View/download PDF

35. Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials.

Author

Lee, Yong-Joon, Shin, Sanghoon, Kwon, Sung Woo, Suh, Yongsung, Yun, Kyeong Ho, Kang, Tae Soo, Lee, Jun-Won, Cho, Deok-Kyu, Park, Jong-Kwan, Bae, Jang-Whan, Kang, Woong Cheol, Kim, Seunghwan, Lee, Seung-Jun, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, and Jang, Yangsoo

Subjects
ACUTE coronary syndrome, PLATELET aggregation inhibitors, MYOCARDIAL infarction, CLINICAL trials, TICAGRELOR
Abstract

Background and Aims In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is recommended for 12 months after drug-eluting stent (DES) implantation. Monotherapy with a potent P2Y12 inhibitor after short-term DAPT is an attractive option to better balance the risks of ischaemia and bleeding. Therefore, this study evaluated the efficacy and safety of ticagrelor monotherapy after short-term DAPT, especially in patients with ACS. Methods Electronic databases were searched from inception to 11 November 2023, and for the primary analysis, individual patient data were pooled from the relevant randomized clinical trials comparing ticagrelor monotherapy after short-term (≤3 months) DAPT with ticagrelor-based 12-month DAPT, exclusively in ACS patients undergoing DES implantation. The co-primary endpoints were ischaemic endpoint (composite of all-cause death, myocardial infarction, or stroke) and bleeding endpoint [Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding] at 1 year. Results Individual patient data from two randomized clinical trials including 5906 ACS patients were analysed. At 1 year, the primary ischaemic endpoint did not differ between the ticagrelor monotherapy and ticagrelor-based DAPT groups [1.9% vs. 2.5%; adjusted hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.56–1.13; P =.194]. The incidence of the primary bleeding endpoint was lower in the ticagrelor monotherapy group (2.4% vs. 4.5%; adjusted HR 0.54; 95% CI 0.40–0.72; P <.001). The results were consistent in a secondary aggregate data meta-analysis including the ACS subgroup of additional randomized clinical trials which enrolled patients with ACS as well as chronic coronary syndrome. Conclusions In ACS patients undergoing DES implantation, ticagrelor monotherapy after short-term DAPT was associated with less major bleeding without a concomitant increase in ischaemic events compared with ticagrelor-based 12-month DAPT. Study registration PROSPERO (ID: CRD42023476470). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease: a clinical trial.

Author

Ko, Young-Guk, Lee, Seung-Jun, Ahn, Chul-Min, Lee, Sang-Hyup, Lee, Yong-Joon, Kim, Byeong-Keuk, Hong, Myeong-Ki, Jang, Yangsoo, Kim, Tae-Hoon, Park, Ha-Wook, Jang, Ji Yong, Lee, Jae-Hwan, Park, Jae-Hyeong, Kim, Su Hong, Im, Eui, Park, Sang-ho, Choi, Donghoon, and investigators, IVUS-DCB

Subjects
INTRAVASCULAR ultrasonography, TRANSLUMINAL angioplasty, ENDOVASCULAR surgery, PERIPHERAL vascular diseases, ARTERIAL diseases
Abstract

Background and Aims Drug-coated balloons (DCBs) have demonstrated favourable outcomes following endovascular therapy for femoropopliteal artery (FPA) disease. However, uncertainty remains whether the use of intravascular ultrasound (IVUS) can improve the outcomes of DCBs. Methods This prospective, multicentre, randomized trial, conducted at seven centres in South Korea, compared the outcomes of IVUS-guided vs. angiography-guided angioplasty for treating FPA disease with DCBs. Patients were assigned to receive IVUS-guided (n = 119) or angiography-guided (n = 118) angioplasty using DCBs. The primary endpoint was 12-month primary patency. Results Between May 2016 and August 2022, 237 patients were enrolled and 204 (86.0%) completed the trial (median follow-up; 363 days). The IVUS guidance group showed significantly higher primary patency [83.8% vs. 70.1%; cumulative difference 19.6% (95% confidence interval 6.8 to 32.3); P =.01] and increased freedom from clinically driven target lesion revascularization [92.4% vs. 83.0%; difference 11.6% (95% confidence interval 3.1 to 20.1); P =.02], sustained clinical improvement (89.1% vs. 76.3%, P =.01), and haemodynamic improvement (82.4% vs. 66.9%, P =.01) at 12 months compared with the angiography guidance group. The IVUS group utilized larger balloon diameters and pressures for pre-dilation, more frequent post-dilation, and higher pressures for post-dilation, resulting in a greater post-procedural minimum lumen diameter (3.90 ± 0.59 vs. 3.71 ± 0.73 mm, P =.03). Conclusions Intravascular ultrasound guidance significantly improved the outcomes of DCBs for FPA disease in terms of primary patency, freedom from clinically driven target lesion revascularization, and sustained clinical and haemodynamic improvement at 12 months. These benefits may be attributed to IVUS-guided optimization of the lesion before and after DCB treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction

Author

Lee, Seung-Jun, Cho, Jae Young, Kim, Byeong-Keuk, Yun, Kyeong Ho, Suh, Yongsung, Cho, Yun-Hyeong, Kim, Yong Hoon, Her, Ae-Young, Cho, Sungsoo, Jeon, Dong Woon, Yoo, Sang-Yong, Cho, Deok-Kyu, Hong, Bum-Kee, Kwon, Hyuck Moon, Hong, Sung-Jin, Ahn, Chul-Min, Shin, Dong-Ho, Nam, Chung-Mo, Kim, Jung-Sun, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, and Jang, Yangsoo

Published
2021
Full Text
View/download PDF

45. Treat-to-target or high-intensity statin treatment in older adults with coronary artery disease: a post hoc analysis of the LODESTAR trial.

Author

Lee, Seung-Jun, Lee, Jin-Bae, Yang, Tae-Hyun, Kang, Woong Chol, Lee, Jong-Young, Lee, Yong-Joon, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Hong, Bum-Kee, Choi, Donghoon, Yoon, Junghan, Jang, Yangsoo, Hong, Myeong-Ki, and investigators, for the LODESTAR

Subjects
MYOCARDIAL infarction risk factors, MORTALITY risk factors, PATIENT safety, RESEARCH funding, SECONDARY analysis, TREATMENT effectiveness, DESCRIPTIVE statistics, LDL cholesterol, AGE distribution, MYOCARDIAL revascularization, STATINS (Cardiovascular agents), DRUG efficacy, CORONARY artery disease, CONFIDENCE intervals, STROKE, EVALUATION, DISEASE risk factors, OLD age
Abstract

Background The optimal statin treatment strategy that is balanced for both efficacy and safety has not been clearly determined in older adults with coronary artery disease (CAD). Methods In the post hoc analysis of the LODESTAR (low-density lipoprotein cholesterol-targeting statin therapy versus intensity-based statin therapy in patients with coronary artery disease) trial, the impact between a treat-to-target strategy versus a high-intensity statin therapy strategy was compared in older adults (aged 75 years or older). The goal of treat-to-target low-density lipoprotein cholesterol (LDL-C) level was 50–70 mg/dl. The primary endpoint comprised the three-year composite of all-cause death, myocardial infarction, stroke or coronary revascularisation. Results Among 4,400 patients with CAD enrolled in the LODESTAR trial, 822 (18.7%) were aged 75 years or older. Poor clinical outcomes and risk factors for atherosclerosis were more frequently observed in older adults than in younger population (<75 years old). Among these older adults with CAD, the prescription rate of high-intensity statin was significantly lower in the treat-to-target strategy group throughout the study period (P  < 0.001). The mean LDL-C level for three years was 65 ± 16 mg/dl in the treat-to-target strategy group and 64 ± 18 mg/dl in the high-intensity statin group (P  = 0.34). The incidence of primary endpoint occurrence was 10.9% in the treat-to-target strategy group and 12.0% in the high-intensity statin group (hazard ratio 0.92, 95% confidence interval 0.61–1.38, P  = 0.69). Conclusions High-intensity statin therapy is theoretically more necessary in older adults because of worse clinical outcomes and greater number of risk factors for atherosclerosis. However, the primary endpoint occurrence with a treat-to-target strategy with an LDL-C goal of 50–70 mg/dl was comparable to that of high-intensity statin therapy and reduced utilisation of a high-intensity statin. Taking efficacy as well as safety into account, adopting a tailored approach may be considered for this high-risk population. Trial Registration ClinicalTrials.gov , NCT02579499. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results